International Clinical Advisory Board Appointments

RNS Number : 2153K
Surgical Innovations Group PLC
23 June 2014



Press Release

23 June 2014


Surgical Innovations Group plc


("SI" or the "Group" or the "Company")


International Clinical Advisory Board Appointments


Surgical Innovations Group plc (AIM: SUN), a leading creator of innovative medical technology addressing unmet clinical needs in minimally invasive surgery, announces the appointment of two Belgian surgeons Denis Pitot and Jody Valk,  to its International Clinical Advisory Board ('ICAB') with immediate effect.


Denis Pitot graduated from Université Libre de Bruxelles (ULB). He is a digestive surgeon specialised in bariatric surgery at the CHU of Charleroi, specialising in laparoscopy and Single Incision Laparoscopic Surgery ('SILS'). He is a board member of the BeSOMS (Belgian section of Obesity and Metabolic Surgery) and member of the IFSO (International Federation for the Surgery of Obesity).


Jody Valk graduated from the University of Utrecht in the Netherlands in 1998.  He is experienced in thoracic and general surgery and now focuses on upper gastrointestinal and lung surgery.  Since October 2006 he has worked at the ZNA Stuivenberg Hospital. The Belgian hospital is part of the ZNA group, which is one of the 10 largest health care providers in Europe.  Jody is also a member of BeSOMS, IFSO and the ESTS (European Society of Thoracic Surgeons).


The ICAB complements the well-established UK CAB and gives SI the opportunity to build relationships with the surgeons who are leading medical technology innovations across Europe. Denis and Jody are both experienced surgeons and have been introduced to ICAB after extensive collaboration with SI's Belgian distributor, Duomed.


Graham Bowland, Chief Executive Officer for Surgical Innovations, commented: "SI is delighted to welcome Denis and Jody to the ICAB.  Our five ICAB members ensure that the Group are given the most up to date and holistic view of the international market SI operates in, together with the most accurate feedback on the developing MIS products that we design and manufacture globally."






For further information please contact:

Surgical Innovations Group plc

Graham Bowland, Chief Executive Officer

Mike Thornton, Chief Financial Officer

Tel:  +44 (0) 113 230 7597

Nominated Advisor and Broker

Panmure Gordon

Freddy Crossley (Corporate Finance)

Tel:  +44 (0) 207 886 2500


Media Enquiries

Abchurch Communications

Jamie Hooper / Stephanie Watson

Tel: +44 (0) 207 398 7719


Notes to Editors:

Surgical Innovations Group plc (AIM: SUN) is a highly reputable British-based medical device designer and manufacturer, focused on delivering clinical solutions for surgeons that are both cost-effective and efficient. Since the Group's inception in 1992, it has established itself as a pioneer within the laparoscopic surgery field through a successfully developed portfolio of innovative medical devices.


Surgical Innovations' innovative products are centred on its Resposable® concept which utilises a combination of disposable and reusable components to deliver cost-efficient solutions to healthcare organisations. Within the Group's SI Brand division, the portfolio of products includes port access systems, instrumentation and retraction devices.


The technologies used in SI's laparoscopic products can be adapted to meet the needs of surgeons in other specialties of minimally invasive surgery (MIS), including hip arthroscopy, cardiac and thoracic. SI is currently working with leading clinicians to develop tailored solutions in these emerging areas of MIS surgery. SI has successfully adapted its technology to the industrial sector, conducting "keyhole surgery" on jet engines, creating revenue streams from both development work and eventual device sales.


The business has a compelling market position with an established international footprint. Through its developed network of distribution partners, Surgical Innovations' branded products are being sold in all the major high growth medical device markets. With a balanced investment strategy focused on R&D, manufacturing, coupled with sales and marketing and clinical training, the Group is well positioned and has the management expertise in place to capitalise on the growing demand, gain market share and deliver return to shareholders.


For more information, please see


This information is provided by RNS
The company news service from the London Stock Exchange
UK 100

Latest directors dealings